logo
  Join        Login             Stock Quote

Mylan (MYL) Launches Generic Version Of Osteoporosis Treatment In UK, Italy

 May 24, 2012 02:43 PM
 


(By Balachander) Mylan Inc. (NASDAQ:MYL), one of the world's largest generic drugmakers, announced the launch of generic version of Roche's osteoporosis treatment Bonviva in the UK and Italy.

The Canonsburg, Pennsylvania-based company said the launch of generic Ibandronic Acid tablets expands its strong portfolio of more than 350 products in the UK and 340 products in Italy.

Osteoporosis is the thinning of bone tissue and loss of bone density over time, common in older women.

Ibandronic Acid Film Coated Tablets POM had sales of about 8.5 million euros ($10.65 million) in the UK and sales of about 27 million euros in Italy for the 12 months ending March 2012, according to IMS Health.

[Related -Mylan, Inc. (MYL) Q3 Earnings Preview: Weak Dollar = Strong Profit?]

On Wednesday, Mylan said its subsidiary launched the generic version of Viramune tablets to treat patients living with HIV/AIDS, after final approval from the U.S. health regulators. This expands further the reach of Mylan's global antiretroviral portfolio.

Last week, the company announced the launch of generic version of Sanofi-Aventis' (NYSE: SNY) Plavix blood thinning tablets indicated for acute coronary syndrome. Mylan's Pharmaceuticals Inc. unit has received final clearance from the U.S. health regulators for its Abbreviated New Drug Application (ANDA) for Clopidogrel Tablets USP, 75 mg and 300 mg.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

Earlier this month, Mylan announced the launch of the generic version of Pfizer's (NYSE: PFE) Lipitor, the top-selling cholesterol controlling drug, in France, Belgium, the UK, the Netherlands and Ireland.

MYL shares, which have been trading in the 52-week range of $15.49 to $25.00, added 0.67 percent to trade at $21.04 on Thursday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageCrude Rebound

Since the price of crude oil broke below $90 per barrel in September, the Brent global benchmark has been read on...

article imageShould You Invest In The Hottest New Trend In Finance?

Thanks to major changes in regulation, social media and technology, the business of banking has undergone read on...

article imageStrong Attractor in Action Pulling S&P 500 Down

The attractor is formed by the 200-day moving average and the 50% Fibonacci retracement of the up move from read on...

article imageIs The Weak Housing Market A Warning Sign For The US Economy?

Today’s US economic releases – housing starts and business survey data for the manufacturing sector – read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.